Mercer Global Advisors
ELVN icon

Mercer Global Advisors’s Enliven Therapeutics ELVN Stock Holding History

Mercer Global Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
+729
New +$30.9K ﹤0.01% 4489

Other funds holding ELVN

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mercer Global Advisors's ELVN Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 729 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #4489 among its holdings.

173 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Mercer Global Advisors held 729 shares of Enliven Therapeutics worth $37K as of Q2 2026.
  • Enliven Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4489 holding.
  • 173 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.